In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.
Uncovering the Prevalence of Type 1 Diabetes in Older Adults
Concentrating on the MOMPOD Trial for Metformin Plus Insulin
Utilizing Hybrid Closed-Loop Technology for T1D Pediatric Patients
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients
Strategies for Addressing Diabetes Stigma and Discrimination
How the Artificial Pancreas Can Help Diabetic Patients
Using CGMs and Insulin Pumps to Treat Pediatric Patients with T1D
Challenging the Misconception That T1D Is a Childhood-Onset Disease
Decoding Diabetes Diversity: A Study on Heterogeneity and Endotypes in T1D
Why Hybrid Closed-Loop Insulin Therapy Should Be Offered to Pregnant T1D Patients
Discussing a T2D Medication That Could Reduce Insulin Needs in T1D
How Overnight Glucose Levels Impact Daily Activities in T1D Patients
Breaking Down Biosimilar Insulins: A Look at the Regulatory Process and Impacts
Educating Providers and Patients About Insulin Biosimilars
How Ultra-Processed Foods Increase the Risk of Type 2 Diabetes
Recapping a Narrative Review on the Management of Chronic Kidney Disease in T2D
The Impact of RADIANT: A Deep Dive into the Study
Guiding Principles of Treating Gestational Diabetes
How Diet Can Affect the Gut Microbiome
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video